Caribou Biosciences, Inc. Operating Income Loss

• Caribou Biosciences, Inc. showed an increase of +11.0% in Operating Income Loss from 2024 to 2025.
• This data is from Caribou Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Caribou Biosciences, Inc.'s Operating Income Loss has declined by 332.4%.
• Historical annual values: Fiscal year 2025: -$148.34 million | Fiscal year 2024: -$166.62 million | Fiscal year 2023: -$116.06 million | Fiscal year 2022: -$106.40 million | Fiscal year 2021: -$66.98 million | Fiscal year 2020: -$36.12 million | Fiscal year 2019: -$34.31 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026